Antibodies as crypts of antiinfective and antitumor peptides

Current Medicinal Chemistry

Volumn 16, Issue 18, 2009, Pages 2305-2323

  Magliani, W ^a   Conti, S ^a   Cunha, R L O R ^b   Travassoss, L R ^c   Polonelli, L ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Unidade de Oncologia Experimental   (Brazil)

Author keywords

Antibodies; Antiinfective peptides; Antitumor peptides; Killer peptides; Microbicidal antibodies; Synthetic CDRs; Therapeutic antibodies

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; AMPHOTERICIN B; ANTIINFECTIVE AGENT; BETA GLUCAN; ENFUVIRTIDE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; KILLER PEPTIDE; LACTOFERRICIN; LAMINARAN; MONOCLONAL ANTIBODY; MOTAVIZUMAB; MYCOGRAB; PALIVIZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PEPTIDE;

ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIGEN BINDING; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; BINDING SITE; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; COMPLEMENTARITY DETERMINING REGION; CYTOTOXICITY; DIMERIZATION; DOWN REGULATION; DRUG BINDING; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; MELANOMA CELL; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PROTEIN PHOSPHORYLATION; REPRODUCIBILITY; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS INFECTION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; COMMUNICABLE DISEASE; DRUG DESIGN; IMMUNOLOGY; MOLECULAR GENETICS; NEOPLASM;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMMUNICABLE DISEASES; DRUG DESIGN; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NEOPLASMS; PEPTIDES;

EID: 67949085218     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788453104     Document Type: Review

References (180)

1. Carter, P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol., 2006, 6, 343-357.
2. Litman, G.W.; Cannon, J.P.; Dishaw, L.J. Reconstructing immune phylogeny: New perspectives. Nat. Rev. Immunol., 2005, 5, 866-879.
3. Delves, P.J.; Roitt, I.M. The immune system. First of two parts. N. Engl. Med., 2000, 343, 37-49.
4. Delves, P.J.; Roitt, I.M. The immune system. Second of two parts. N. Engl. Med., 2000, 343, 108-117.
5. Torres, M.; Casadevall, A. The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol., 2008, 29, 91-97.
6. Tonegawa, S. Somatic generation of antibody diversity. Nature, 1983, 302, 575-581.
7. Maizels, N. Immunoglobulin gene diversification. Annu. Rev. Genet., 2005, 39, 23-46.
8. Di Noia, J.M.; Neuberger, M.S. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem., 2007, 76, 1-22.
9. Peled J.U.; Kuang, F.L.; Iglesias-Ussel, M.D.; Roa, S.; Kalis, S.L.; Goodman, M.F.; Scharff, M.D. The biochemistry of somatic hypermutation. Annu. Rev. Immunol., 2008, 26, 481-511.
10. Dudley, D.D.; Chaudhuri, J.; Bassing, C.H.; Alt, F.W. Mechanism and control of V(D)J recombination versus class switch recombination: similarities and differences. Adv. Immunol., 2005, 86, 43-112.
11. Longerich, S.; Basu, U.; Alt, F.; Storb, U. AID in somatic hypermutation and class switch recombination. Curr. Opin. Immunol., 2006, 18, 164-174.
12. Paul, S.; Nishiyama, Y.; Planque, S.; Karle, S.; Taguchi, H.; Hanson, C.; Weksler, M.E. Antibodies as defensive enzymes. Springer Semin. Immunopathol., 2005, 26, 485-503.
13. Sanderson, C.J.; Clark, I.A.; Taylor, G.A. Different effector cell types in antibody-dependent cell-mediated cytotoxicity. Nature, 1975, 253, 376-377.
14. Gale, R.P.; Zighelboim, J. Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity. J. Immunol., 1975, 114, 1047-1051.
15. Casadevall, A.; Pirofski, L-A. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv. Immunol., 2006, 91, 1-44.
16. Igietseme, J.U.; Eko, F.O.; He, Q.; Black, C.M. Antibody regulation of T cell immunity: Implications for vaccine strategies against intracellular pathogens. Expert Rev. Vacc., 2004, 3, 23-34.
17. Magliani, W.; Conti, S.; Frazzi, R.; Ravanetti, L.; Maffei, D.L.; Polonelli, L. Protective antifungal yeast killer toxin-like antibodies. Curr. Mol. Med., 2005, 5, 443-452.
18. Magliani, W.; Conti, S.; Gerloni, M.; Bertolotti, D.; Polonelli, L. Yeast killer systems. Clin. Microbiol. Rev., 1997, 10, 369-400.
19. Polonelli, L.; De Bernardis, F.; Conti, S.; Boccanera, M.; Magliani, W.; Gerloni, M.; Cantelli, C.; Cassone, A. Human natural yeast killer toxin-like candidacidal antibodies. J. Immunol., 1996, 156, 1880-1885.
20. Magliani, W.; Conti, S.; De Bernardis, F.; Gerloni, M.; Bertolotti, D.; Mozzoni, P.; Cassone, A.; Polonelli, L. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol., 1997, 15, 155-158.
21. Polonelli, L.; Seguy, N.; Conti, S.; Gerloni, M.; Bertolotti, D.; Cantelli, C.; Magliani, W.; Cailliez, J.C. Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin. Diagn. Lab. Immunol., 1997, 4, 142-146.
22. Séguy, N.; Cailliez, J.C.; Delcourt, P.; Conti, S.; Camus, D.; Dei-Cas, E.; Polonelli, L. Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii. Mol. Med., 1997, 3, 544-552.
23. Conti, S.; Fanti, F.; Magliani, W.; Gerloni, M.; Bertolotti, D.; Salati, A.; Cassone, A.; Polonelli, L. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. J. Infect. Dis., 1998, 177, 807-811.
24. Conti, S.; Magliani, W.; Arseni, S.; Dieci, E.; Frazzi, R.; Salati, A.; Varaldo, P.E.; Polonelli, L. In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic-resistant gram-positive cocci. Mol. Med., 2000, 6/7, 613-619.
25. Conti, S.; Magliani, W.; Arseni, S.; Frazzi, R.; Salati, A.; Ravanetti, L.; Polonelli, L. Inhibition by yeast killer toxin-like antibodies of oral Streptococci adhesion to tooth surfaces in an ex vivo model. Mol. Med., 2002, 8, 313-317.
26. Cenci, E.; Mencacci, A.; Spreca, A.; Montagnoli, C.; Bacci, A.; Perruccio, K.; Velardi, A.; Magliani, W.; Conti, S.; Polonelli, L.; Romani, L. Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect. Immun., 2002, 70, 2375-2382.
27. Magliani, W.; Conti, S.; Giovati, L.; Maffei, D.L.; Polonelli, L. Anti-beta-glucan-like immunoprotective candidacidal antiidiotypic antibodies. Front. Biosci., 2008, 13, 6920-6937
28. Bromuro, C.; Torosantucci, A.; Chiani, P.; Conti, S.; Polonelli, L.; Cassone, A. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun., 2002, 70, 5462-5470.
29. Torosantucci, A.; Bromuro, C.; Chiani, P.; De Bernardis, F.; Berti, F.; Galli, C.; Norelli, F.; Bellucci, C.; Polonelli, L.; Costantino, P.; Rappuoli, R.; Cassone, A. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med., 2005, 202, 597-606.
30. Rachini, A.; Pietrella, D.; Lupo, P.; Torosantucci, A.; Chiani, P.; Bromuro, C.; Proietti, C.; Bistoni, F.; Cassone, A.; Vecchiarelli, A. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun., 2007, 75, 5085-5094.
31. Köhler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256, 495-497.
32. Chiarella, P.; Fazio, V.M. Mouse monoclonal antibodies in biological research: Strategies for high-throughput production. Biotechnol. Lett., 2008, 30, 1303-1310.
33. Almagro, J.C.; Fransson, J. Humanization of antibodies. Front. Biosci., 2008, 13, 1619-1633.
34. Lonberg, N. Human monoclonal antibodies from transgenic mice. Handb. Exp. Pharmacol., 2008, 181, 69-97.
35. Hoogenboom, H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol., 2005, 23, 1105-1116.
36. Mondon, P.; Dubreuil, O.; Bouayadi, K.; Kharrat, H. Human antibody libraries: A race to engineer and explore a larger diversity. Front. Biosci., 2008, 13, 1117-1129.
37. Schirrmann, T.; Al-Halabi, L.; Dübel, S.; Hust, M. Production systems for recombinant antibodies. Front. Biosci., 2008, 13, 4576-4594.
38. Buckler, D.R.; Park, A.; Viswanathan, M.; Hoet, R.M.; Ladner, R.C. Screening isolates from antibody phage-display libraries. Drug Discov. Today, 2008, 13, 318-324.
39. Hudson, P.J., Souriau, C. Engineered antibodies. Nat. Med., 2003, 9, 129-134.
40. Holliger, P.; Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol., 2005, 23, 1126-1136.
41. Donzeau, M.; Knappik, A. Recombinant monoclonal antibodies. Methods Mol. Biol., 2007, 378, 14-31.
42. Demarest, S.J.; Glaser, S.M. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr. Opin. Drug Discov. Devel., 2008, 11, 675-687.
43. Liu, X.Y.; Pop, L.M.; Vitetta, E.S. Engineering therapeutic monoclonal antibodies. Immunol. Rev., 2008, 222, 9-27.
44. Holt, L.J.; Herring, C.; Jespers, L.S.; Woolven, B.P.; Tomlinson, I.M. Domain antibodies: Proteins for therapy. Trends Biotechnol., 2003, 21, 484-490.
45. Tanha, J.; Nguyen, T.D.; Ng, A.; Ryan, S.; Ni, F.; Mackenzie, R. Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach. Protein Eng. Des. Sel., 2006, 19, 503-509.
46. Kovtun, Y.V.; Goldmacher, V.S. Cell killing by antibody-drug conjugates. Cancer Lett., 2007, 255, 232-240.
47. Carter, P.J.; Senter, P.D. Antibody-drug conjugates for cancer therapy. Cancer J., 2008, 14, 154-169.
48. Chari, R.V. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc. Chem. Res., 2008, 41, 98-107.
49. Lo, A.S.; Zhu, Q.; Marasco, W.A. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb. Exp. Pharmacol., 2008, 181, 343-373.
50. Cardinale, A.; Biocca, S. Combating protein misfolding and aggregation by intracellular antibodies. Curr. Mol. Med., 2008, 8, 2-11.
51. Muller, S.; Zhao, Y.; Brown, T.L.; Morgan, A.C.; Kohler, H. TransMabs: cell-penetrating antibodies, the next generation. Expert Opin. Biol. Ther., 2005, 5, 237-241.
52. Humphreys, D.P.; Heywood, S.P.; Henry, A.; Ait-Lhadj, L.; Antoniw, P.; Palframan, R.; Greenslade, K.J.; Carrington, B.; Reeks, D.G.; Bowering, L.C.; West, S.; Brand, H.A. Alternative antibody Fab' fragment PEGylation strategies: Combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Eng. Des. Sel., 2007, 20, 227-234.
53. Presta, L.G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol., 2008, 20, 460-470.
54. Mazor, Y.; Van Blarcom, T.; Mabry, R.; Iverson, B.L.; Georgiou, G. Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat. Biotechnol., 2007, 25, 563-565.
55. von Behring, E.A.; Kitasato, S. Ueber das Zustandekommen der Diptherie-Immunität und der Tetanus-Immunität bei Thieren. Deutch. Med. Woch., 1890, 49, 1113-1114.
56. Casadevall, A.; Scharff, M.D. Return to the past: The case for antibody-based therapies in infectious diseases. Clin. Infect. Dis., 1995, 21, 150-161.
57. Newcombe, C.; Newcombe, A.R. Antibody production: Polyclonal-derived biotherapeutics. J. Chromatogr. B, 2007, 848, 2-7
58. Stockwin, L.H.; Holmes, S. Antibodies as therapeutic agents: Vive la renaissance! Expert Opin. Biol. Ther., 2003, 3, 1133-1152.
59. Goldstein G. Overview of the development of Orthoclone OKT3: Monoclonal antibody for therapeutic use in transplantation. Transplant. Proc., 1987, 19 (Suppl. 1), 1-6.
60. Beck, A.; Wurch, T.; Corvaïa, N. Editorial: Therapeutic antibodies and derivatives: From the bench to the clinic. Curr. Pharm. Biotechnol., 2008, 9, 421-422.
61. Reichert, J.M. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol., 2008, 9, 423-430.
62. Thie, H.; Meyer, T.; Schirrmann, T.; Hust, M.; Dübel, S. Phage display derived therapeutic antibodies. Curr. Pharm. Biotechnol., 2008, 9, 439-446.
63. Steinmeyer, D.E.; McCormick, E.L. The art of antibody process development. Drug Discov. Today, 2008, 13, 613-618.
64. Tcheng, J.E. Dosing and administration of ReoPro (c7E3 Fab). J. Invasive Cardiol., 1994, 6 (Suppl A), 29-33.
65. Gralla, J.; Rennie, A.T.; Corkill, R.A.; Lalloo, S.T.; Molyneux, A.; Byrne, J.V.; Kuker, W. Abciximab for thrombolysis during intracranial aneurysm coiling. Neuroradiology, 2008, 50, 1041-1047.
66. Coiffier, B.; Haioun, C.; Ketterer, N.; Engert, A.; Tilly, H.; Ma, D.; Johnson, P.; Lister, A.; Feuring-Buske, M.; Radford, J.A.; Capdeville, R.; Diehl, V.; Reyes, F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood, 1998, 92, 1927-1932.
67. Newsome, B.W.; Ernstoff, M.S. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br. J. Clin. Pharmacol., 2008, 66, 6-19.
68. Castillo, J.; Winer, E.; Quesenberry, P. Newer monoclonal antibodies for hematological malignancies. Exp. Hematol., 2008, 36, 755-768.
69. Sawyers, C. Targeted cancer therapy. Nature, 2004, 432, 294-297.
70. Imai, K.; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nature, 2006, 6, 714-727.
71. James, D.F.; Kipps, T.J. Alemtuzumab in chronic lymphocytic leukemia. Future Oncol., 2007, 3, 29-42.
72. Fanale, M.A.; Younes, A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs, 2007, 67, 333-350
73. Robak, T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr. Cancer Drug Targets, 2008, 8, 156-171.
74. Horton, H.M.; Bernett, M.J.; Pong, E.; Peipp, M.; Karki, S.; Chu, S.Y.; Richards, J.O.; Vostiar, I.; Joyce, P.F.; Repp, R.; Desjarlais, J.R.; Zhukovsky, E.A. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res., 2008, 68, 8049-8057.
75. Clynes, R. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol. Oncol. Clin. North Am., 2006, 20, 585-612.
76. Roque-Navarro, L.; Chakrabandhu, K.; de León, J.; Rodríguez, S.; Toledo, C.; Carr, A.; de Acosta, C.M.; Hueber, A.O.; Pérez, R. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol. Cancer Ther., 2008, 7, 2033-2041.
77. Metro, G.; Mottolese, M.; Fabi, A. HER-2-positive metastatic breast cancer: Trastuzumab and beyond. Expert Opin. Pharmacother., 2008, 9, 2583-2601.
78. Banerjee, D.; Matthews, P.; Matayeva, E.; Kaufman, J.L.; Steinman, R.M.; Dhodapkar, K.M. Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcgammaRs on human dendritic cells. J. Immunother., 2008, 31, 113-120.
79. Yan, L.; Hsu, K.; Beckman, R.A. Antibody-based therapy for solid tumors. Cancer J., 2008, 14, 178-83.
80. Norden, A.D.; Drappatz, J.; Wen, P.Y. Antiangiogenic therapy in malignant gliomas. Curr. Opin. Oncol., 2008, 20, 652-661.
81. Rose, J.W.; Foley, J.; Carlson, N. Monoclonal antibody treatments for multiple sclerosis. Curr. Neurol. Neurosci. Rep., 2008, 8, 419-426.
82. Lynch, S.M.; Zhou, C.; Messer, A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol., 2008, 377, 136-147.
83. Prenner, B.M. Asthma 2008: Targeting immunoglobulin E to achieve disease control. J. Asthma, 2008, 45, 429-436.
84. Cambridge, G.; Leandro, M.; Edwards, J.; Ehrenstein, M.; Salden, M.; Bodman-Smith, M.; Webster, A. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum., 2003, 48, 2146-2154.
85. Vega, O.; Cárdenas, G.; Correa-Rotter, R.; Alberú, J.; Morales-Buenrostro, L.E. Basiliximab vs. limited-dose daclizumab (2 mg/ kg) administered in single or two separated doses in kidney transplantation. Rev. Invest. Clin., 2008, 60, 82-86.
86. Sharkey, R.M.; Goldenberg, D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med., 2005, 46, 115s-127s.
87. Mulford, D.A.; Scheinberg, D.A.; Jurcic, J.G. The promise of targeted alpha-particle therapy. J. Nucl. Med., 2005, 46, 199s-204s.
88. Sofou, S. Radionuclide carriers for targeting of cancer. Int. J. Nanomed., 2008, 3, 181-199.
89. Dadachova, E.; Revskaya, E.; Sesay, M.A.; Damania, H.; Boucher, R.; Sellers, R.S.; Howell, R.C.; Burns, L.; Thornton, G.B.; Natarajan, A.; Mirick, G.R.; DeNardo, S.J.; DeNardo, G.L.; Casadevall, A. Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol. Ther., 2008, 7, 1116-1127
90. Stasi, R. Gemtuzumab ozogamicin: An anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin. Biol. Ther., 2008, 8, 527-540.
91. Potala, S.; Sahoo, S.K.; Verma, R.S. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. Drug Discov. Today, 2008, 13, 807-815.
92. Bhatti, M.; Yahioglu, G.; Milgrom, L.R.; Garcia-Maya, M.; Chester, K.A.; Deonarain, M.P. Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int. J. Cancer, 2008, 122, 1155-1163.
93. Baxevanis, C.N.; Perez, S.A.; Papamichail, M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother., 2009, 58, 317-324.
94. Romero, J.R. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: Results from four years of palivizumab usage. Pediatr. Infect. Dis. J., 2003, 22, S46-54.
95. Reichert, J.M.; Dewiz, M.C. Anti-infective monoclonal antibodies: Perils and promise of development. Nat. Rev. Drug Discov., 2006, 5, 191-195.
96. Wu, H.; Pfarr, D.S.; Losonsky, G.A.; Kiener, P.A. Immunoprophylaxis of RSV infection: Advancing from RSV-IGIV to palivizumab and motavizumab. Curr. Top. Microbiol. Immunol., 2008, 317, 103-123.
97. Xiao, X.; Dimitrov, D.S. Monoclonal antibodies against viruses and bacteria: A survey of patents. Recent Patents Anti-Infect. Drug Disc., 2007, 2, 171-197.
98. Weisman, L.E. Antibody for the prevention of neonatal noscocomial staphylococcal infection: A review of the literature. Arch. Pediatr., 2007, 14, S31-34.
99. Casadevall, A. The third age of antimicrobial therapy. Clin. Infect. Dis., 2006, 42, 1414-1416.
100. Singla, M. Antibody based target tailored antimicrobial chemotherapy - a new approach. Med. Hypotheses, 2007, 68, 957-959
101. Hamad, M. Antifungal immunotherapy and immunomodulation: A double-hitter approach to deal with invasive fungal infections. Scand. J. Immunol., 2008, 67, 533-543.
102. Dadachova, E.; Casadevall, A. Treatment of infection with radiolabeled antibodies. Q. J. Nucl. Med. Mol. Imaging, 2006, 50, 193-204.
103. Bryan, R.A.; Huang, X.; Morgenstern, A.; Bruchertseifer, F.; Casadevall, A.; Dadachova, E. Radiofungicidal effects of external gamma radiation and antibody-targeted beta and alpha radiation on Cryptococcus neoformans. Antimicrob. Agents Chemother., 2008, 52, 2232-2235.
104. Casadevall, A.; Goldstein, H.; Dadachova, E. Targeting viruses-harboring host cells with radiolabeled antibodies. Expert Opin. Biol. Ther., 2007, 7, 595-597.
105. Wang, X.G.; Revskaya, E.; Bryan, R.A.; Strickler, H.D.; Burk, R.D.; Casadevall, A.; Dadachova, E. Treating cancer as an infectious disease: viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. PLoS ONE, 2007, 2, e1114.
106. Dadachova, E.; Casadevall, A. Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases. Curr. Opin. Investig. Drugs, 2008, 9, 184-188.
107. Nooney, L.; Matthews, R.C.; Burnie, J.P. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis., 2005, 51, 19-29.
108. Pachl, J.; Svoboda, P.; Jacobs, F.; Vandewoude, K.; van der Hoven, B.; Spronk, P.; Masterson, G.; Malbrain, M.; Aoun, M.; Garbino, J.; Takala, J.; Drgona, L.; Burnie, J.; Matthews, R.; Mycograb Invasive Candidiasis Study Group. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis., 2006, 42, 1404-1413.
109. Hodgetts, S.; Nooney, L.; Al-Akeel, R.; Curry, A.; Awad, S.; Matthews, R.; Burnie, J. Efungumab and caspofungin: Pre-clinical data supporting synergy. J. Antimicrob. Chemother., 2008, 61, 1132-1139.
110. Messaoudi, S.; Peyrat, J.F.; Brion, J.D.; Alami, M. Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med. Chem., 2008, 8, 761-782.
111. www.neutecpharma.com/mycograb.html and/aurograb.html (accessed December 22, 2008).
112. Zhang, M.X.; Bohlman, M.C.; Itatani, C.; Burton, D.R.; Parren, P.W.; St Jeor, S.C.; Kozel, T.R. Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect. Immun., 2006, 74, 362-369.
113. De Bernardis, F.; Liu, H.; O'Mahony, R.; La Valle, R.; Bartollino, S.; Sandini, S.; Grant, S.; Brewis, N.; Tomlinson, I.; Basset, R.C.; Holton, J.; Roitt, I.M.; Cassone, A. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J. Infect. Dis., 2007, 195, 149-157.
114. Beninati, C.; Oggioni, M.R.; Boccanera, M.; Spinosa, M.R.; Maggi, T.; Conti, S.; Magliani, W.; De Bernardis, F.; Teti, G.; Cassone, A.; Pozzi, G.; Polonelli, L. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat. Biotechnol., 2000, 18, 1060-1064.
115. Chartrain, M.; Chu, L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression systems: an overview of the current upstream technologies. Curr. Pharm. Biotechnol., 2008, 9, 447-467.
116. Widakowich, C.; de Castro, G.Jr.; de Azambuja, E.; Dinh, P.; Awada, A. Review: Side effects of approved molecular targeted therapies in solid cancers. Oncologist, 2007, 12, 1443-1455.
117. Force, T.; Kerkelä, R. Cardiotoxicity of the new cancer therapeutics - mechanisms of, and approaches to, the problem. Drug Discov. Today, 2008, 13, 778-784.
118. Kreisl, T.N. Neurologic complications of antitumor antibody therapies. Curr. Neurol. Neurosci. Rep., 2008, 8, 259-263
119. Cao, L.; Yu, Y.; Darko, I.; Currier, D.; Mayeenuddin, L.H.; Wan, X.; Khanna, C.; Helman, L.J. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res., 2008, 68, 8039-8048.
120. Feng, Y.; Dimitrov, D.S. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr. Opin. Drug Discov. Devel., 2008, 11, 178-185.
121. Liu, Z.; Yu, Z.; He, W.; Ma, S.; Sun, L.; Wang, F. In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model. Cancer Biother. Radiopharm., 2009, 24, 15-24.
122. Beck, A.; Wagner-Rousset, E.; Bussat, M.C.; Lokteff, M.; Klinguer-Hamour, C.; Haeuw, J.F.; Goetsch, L.; Wurch, T.; Van Dorsselaer A.; Corvaïa, N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol., 2008, 9, 482-501.
123. Wurch, T.; Lowe, P.; Caussanel, V.; Bes, C.; Beck, A.; Corvaïa, N. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: Status on discovery research and clinical validation. Curr. Pharm. Biotechnol., 2008, 9, 502-509.
124. H domains. J. Biol. Chem., 2008, 283, 3639-3654.
125. Padlan, E.A.; Abergel, C.; Tipper, J.P. Identification of specificity-determining residues in antibodies. FASEB J., 1995, 9, 133-139.
126. Heap, C.J.; Wang, Y.; Pinheiro, T.J.; Reading, S.A.; Jennings, K.R.; Dimmock, N.J. Analysis of a 17-amino acid residue, virus-neutralizing microantibody. J. Gen. Virol., 2005, 86, 1791-1800.
127. Saphire, E.O.; Parren, P.W.H.I.; Pantophlet, R.; Zwick, M.B.; Morris, G.M.; Rudd, P.M.; Dwek, R.A.; Stanfield, R.L.; Burton, D.R.; Wilson, I.A. Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design. Science, 2001, 293, 1155-1158.
128. Bourgeois, C.; Bour, J.B.; Aho, L.S.; Pothier, P. Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J. Virol., 1998, 72, 807-810.
129. Dorfman, T.; Moore, M.J.; Guth, A.C.; Choe, H.;, Farzan, M. A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J. Biol. Chem., 2006, 281, 28529-28535.
130. Park, B.W.; Zhang, H.T.; Wu, C.; Berezov, A.; Zhang, X.; Dua, R.; Wang, Q.; Kao, G.; O'Rourke, D.M.; Greene, M.I.; Murali, R. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol., 2000, 18, 194-198.
131. Qiu, X-Q.; Wang, H.; Cai, B.; Wang, L-L.;Yue, S.-T. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat. Biotechnol., 2007, 25, 921-929.
132. Deroo, S.; Fischer, A.; Beaupain, N.; Counson, M.; Boutonnet, N.; Pletinckx, J.; Loverix, S.; Beirnaert, E.; De Haard, H.; Schmit, J.C.; Lasters, I. Non-immunized natural human heavy chain CDR3 repertoires allow the isolation of high affinity peptides mimicking a human influenza hemagglutinin epitope. Mol. Immunol., 2008, 45, 1366-1373.
133. Mozes, E.; Sela, U.; Sharabi, A. A novel synthetic peptide for the specific treatment of lupus: Clinical effects and mechanism of action. Isr. Med. Assoc. J., 2008, 10, 40-42.
134. Sela, U.; Dayan, M.; Hershkoviz, R.; Lider, O.; Mozes, E. A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3. J. Immunol., 2008, 180, 1584-1591.
135. Polonelli, L.; Magliani, W.; Conti, S.; Bracci, L.; Lozzi, L.; Neri, P.; Adriani, D.; De Bernardis, F.; Cassone, A. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun., 2003, 71, 6205-6212.
136. Magliani, W.; Conti, S.; Salati, A.; Arseni, S.; Ravanetti, L.; Frazzi, R.; Polonelli, L. Engineered killer mimotopes: New synthetic peptides for antimicrobial therapy. Curr. Med. Chem., 2004, 11, 1793-800.
137. Magliani, W.; Conti, S.; Salati, A.; Vaccari, S.; Ravanetti, L.; Maffei, D.L.; Polonelli, L. Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Res., 2004, 5, 11-18.
138. Magliani, W.; Conti, S.; Maffei, D.L.; Ravanetti, L.; Polonelli, L. Antiidiotype-derived killer peptides as new potential tools to combat HIV-1 and AIDS-related opportunistic pathogens. Anti-Infect. Agents Med. Chem., 2007, 6, 263-272.
139. Magliani, W.; Conti, S.; Travassos, L.R.; Polonelli, L. From yeast killer toxins to antibiobodies and beyond. FEMS Microbiol. Lett., 2008, 288, 1-8.
140. Manfredi, M.; Merigo, E.; Salati, A.; Conti, S.; Savi, A.; Polonelli, L.; Bonanini, M.; Vescovi, P. In vitro candidacidal activity of a synthetic killer decapeptide (KP) against Candida albicans cells adhered to resin acrylic discs. J. Oral. Pathol. Med., 2007, 36, 468-471.
141. Cenci, E.; Bistoni, F.; Mencacci, A.; Perito, S.; Magliani, W.; Conti, S.; Polonelli, L.; Vecchiarelli, A. A synthetic peptide as a novel anticryptococcal agent. Cell Microbiol., 2004, 6, 953-961.
142. Travassos, L.R.; Silva, L.S.; Rodrigues, E.G.; Conti, S.; Salati, A.; Magliani, W.; Polonelli, L. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J. Antimicrob. Chemother., 2004, 54, 956-958.
143. Manfredi, M.; McCullough, M.J.; Conti, S.; Polonelli, L.; Vescovi, P.; Al-Karaawi Z.M.; Porter, S.R. In vitro activity of a monoclonal killer antiidiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals. Oral Microbiol. Immunol., 2005, 20, 226-232.
144. Savoia, D.; Scutera, S.; Raimondo, S.; Conti, S.; Magliani, W.; Polonelli, L. Activity of an engineered synthetic killer peptide on Leishmania major and Leishmania infantum promastigotes. Exp. Parasitol., 2006, 113, 186-192.
145. Fiori, P.L.; Mattana, A.; Dessi, D.; Conti, S.; Magliani, W.; Polonelli, L. In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide. J. Antimicrob. Chemother., 2006, 57, 891-898.
146. Donini, M.; Lico, C.; Baschieri, S.; Conti, S.; Magliani, W.; Polonelli, L.; Benvenuto, E. Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system. Appl. Environ. Microbiol., 2005, 71, 6360-6367.
147. Casoli, C.; Pilotti, E.; Perno, C.F.; Balestra, E.; Polverini, E.; Cassone, A.; Conti, S.; Magliani, W.; Polonelli, L. A killer mimotope with therapeutic activity against AIDS-related opportunistic microorganisms inhibits ex-vivo HIV-1 replication. AIDS, 2006, 20, 975-980.
148. Conti, G.; Magliani, W.; Conti, S.; Nencioni, L.; Sgarbanti, R.; Palamara, A.T.; Polonelli, L. Therapeutic activity of an antiidiotypic antibody-derived killer peptide against influenza A virus experimental infection. Antimicrob. Agents Chemother., 2008, 52, 4331-4337.
149. Cenci, E.; Pericolini, E.; Mencacci, A.; Conti, S.; Magliani, W.; Bistoni, F.; Polonelli, L.; Vecchiarelli, A. Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. J. Leukoc. Biol., 2006, 79, 40-55.
150. Conti, S.; Magliani, W.; Giovati, L.; Libri, I.; Maffei, D.L.; Salati, A.; Polonelli, L. Screening of a Saccharomyces cerevisiae nonessential gene deletion collection for altered susceptibility to a killer peptide. New Microbiol., 2008, 31, 143-145.
151. Lesage, G.; Bussey, H. Cell wall assembly in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev., 2006, 70, 317-343.
152. Brena, S.; Omaetxebarría, M.J.; Elguezabal, N.; Cabezas, J.; Moragues, M.D.; Pontón, J. Fungicidal monoclonal antibody C7 binds to Candida albicans Als3. Infect. Immun., 2007, 75, 3680-3682.
153. Polonelli, L.; Pontón, J.; Elguezabal, N.; Moragues, M.D.; Casoli, C.; Pilotti, E.; Ronzi, P.; Dobroff, A.S.; Rodrigues, E.G.; Juliano, M.A.; Maffei, D.L.; Magliani, W.; Conti, S.; Travassos, L.R. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS ONE, 2008, 3(6), e2371.
154. Nagy, E.; Giefing, C.; von Gabain, A. Anti-infective antibodies: A novel tool to prevent and treat nosocomial diseases. Expert Rev. Anti Infect. Ther., 2008, 6, 21-30.
155. Morrison, V.A. Echinocandin antifungals: Review and update. Expert Rev. Anti Infect. Ther., 2006, 4, 325-342.
156. Gifford, J.L.; Hunter, H.N.; Vogel, H.J. Lactoferricin: A lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol. Life Sci., 2005, 62, 2588-2598.
157. Chockalingam, A.; Zarlenga, D.S.; Bannerman, D.D. Antimicrobial activity of bovine bactericidal permeability-increasing protein-derived peptides against gram-negative bacteria isolated from the milk of cows with clinical mastitis. Am. J. Vet. Res., 2007, 68, 1151-1159.
158. Mak, P. Hemocidins in a functional and structural context of human antimicrobial peptides. Front. Biosci., 2008, 13, 6859-6871.
159. Cornut, G.; Fortin, C.; Soulières, D. Antineoplastic properties of bacteriocins: Revisiting potential active agents. Am. J. Clin. Oncol., 2008, 31, 399-404.
160. Giuliani, A.; Pirri, G.; Bozzi, A.; Di Giulio, A.; Aschi, M.; Rinaldi, A.C. Antimicrobial peptides: Natural templates for synthetic membrane-active compounds. Cell Mol. Life Sci., 2008, 65, 2450-2460.
161. Hoskin, D.W., Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta, 2008, 1778, 357-375.
162. Rossi, L.M.; Rangasamy, P.; Zhang, J.; Qiu, X.Q.; Wu, G.Y. Research advances in the development of peptide antibiotics. J. Pharm. Sci., 2008, 97, 1060-1070.
163. Marcos, J.F.; Muñoz, A.; Pérez-Payá, E.; Misra, S.; López-García, B. Identification and rational design of novel antimicrobial peptides for plant protection. Annu. Rev. Phytopathol., 2008, 46, 273-301.
164. Smith, L.; Hillman, J. Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr. Opin. Microbiol., 2008, 11, 401-408.
165. Masip, I.; Pérez-Payá, E.; Messeguer, A. Peptoids as source of compounds eliciting antibacterial activity. Comb. Chem. High Throughput Screen., 2005, 8, 235-239.
166. Scott, R.W.; DeGrado, W.F.; Tew, G.N. De novo designed synthetic mimics of antimicrobial peptides. Curr. Opin. Biotechnol., 2008, 19, 620-627.
167. Sforça, M.L.; Machado, A.; Figueredo, R.C.; Oyama, S. Jr.; Silva, F.D.; Miranda, A.; Daffre, S.; Miranda, M.T.; Spisni, A.; Pertinhez, T.A. The micelle-bound structure of an antimicrobial peptide derived from the alpha-chain of bovine hemoglobin isolated from the tick Boophilus microplus. Biochemistry, 2005, 44, 6440-6451.
168. Cutuli, M.; Cristiani, S.; Lipton, J.M.; Catania, A. Antimicrobial effects of alpha-MSH peptides. J. Leukoc. Biol., 2000, 67, 233-239.
169. Giezen, T.J.; Mantel-Teeuwisse, A.K.; Straus, S.M.; Schellekens, H.; Leufkens, H.G.; Egberts, A.C. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA, 2008, 300, 1887-1896.
170. Giusti, R.M.; Cohen, M.H.; Keegan, P,; Pazdur, R. FDA review of a Panitumumab (VectibixTM) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist, 2009 Mar 12 [Epub ahead of print].
171. Lashley, F.R. Emerging infectious diseases at the beginning of the 21st century. Online J. Issues Nurs., 2006, 11, 2.
172. Sipahi, O.R. Economics of antibiotic resistance. Expert Rev. Anti Infect. Ther., 2008, 6, 523-539.
173. Cudic, P.; Stawikowski, M. Peptidomimetics: Fmoc solid-phase pseudopeptide synthesis. Methods Mol. Biol., 2008, 494, 223-246.
174. Liu, S.; Wu, S.; Jiang, S. HIV entry inhibitors targeting gp41: From polypeptides to small-molecule compounds. Curr. Pharm. Des., 2007, 13, 143-162.
175. Marr, P.; Walmsley, S. Reassessment of enfuvirtide's role in the management of HIV-1 infection. Expert Opin. Pharmacother., 2008, 9, 2349-2362.
176. Belperio, P.S.; Mole, L.A.; Halloran, J.; Boothroyd, D.B.; Thomas, I.C.; Backus, L.I. Postmarketing use of enfuvirtide in veterans: Provider compliance with criteria for use, overall efficacy, and tolerability. Ann. Pharmacother., 2008, 42, 1573-1580.
177. Emerson, C.R.; Post, J.J.; Workman, C. A delayed hypersensitivity reaction to enfuvirtide after rechallenge. Int. J. STD AIDS, 2009, 20, 288-289.
178. Matsuzaki, K. Control of cell selectivity of antimicrobial peptides. Biochim. Biophys. Acta, 2008, Oct 8. [Epub ahead of print].
179. Haberkorn, U.; Eisenhut, M.; Altmann, A.; Mier, W. Endoradiotherapy with peptides - status and future development. Curr. Med. Chem., 2008, 15, 219-234.
180. Kaufmann, G.F.; Park, J.; Janda, K.D. Bacterial quorum sensing: A new target for anti-infective immunotherapy. Expert Opin. Biol. Ther., 2008, 8, 719-724.